Product
EGFRt/19-28z/IL-12 CAR T-lymphocytes
1 clinical trial
12 indications
Indication
Chronic Lymphocytic LeukemiaIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
Recurrent Follicular LymphomaIndication
Recurrent High Grade B-Cell LymphomaIndication
Mantle Cell LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Follicular LymphomaIndication
Refractory High Grade B-Cell LymphomaClinical trial
A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2027-06-15